HDAC inhibitors such as VPA or SAHA are currently being developed for various types of malignancies, including breast cancer [6, 58], and are already in clinical use for peripheral T cell lymphomas [59, 60]. This evidence concerns the gene HDAC9 and peripheral T-cell lymphoma, not otherwise specified.